ClinVar Miner

Submissions for variant NM_000404.4(GLB1):c.442C>T (p.Arg148Cys) (rs192732174)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000178094 SCV000230089 pathogenic not provided 2013-07-08 criteria provided, single submitter clinical testing
Counsyl RCV000666298 SCV000790566 likely pathogenic GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Mucopolysaccharidosis, MPS-IV-B; Infantile GM1 gangliosidosis 2017-03-29 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000778692 SCV000915043 pathogenic GM1 gangliosidosis 2017-10-19 criteria provided, single submitter clinical testing Across a selection of the available literature, the GLB1 c.442C>T (p.Arg148Cys) missense variant has been reported in at least five cases of GM1 gangliosidosis, including four of type 1 and one of type 3 (Roze et al. 2005; Kooper et al. 2006; Caciotti et al. 2007; Hofer et al. 2010; Caciotti et al. 2011). Among the four type 1 cases, the p.Arg148Cys variant was found in a homozygous state in one terminated fetus and in an individual who died at age two. It was also reported in a compound heterozygous state with a frameshift or complex allele in two unrelated 16-month-old individuals who presented with pyschomotor delay before one year of age. The type 3 case developed progressive generalized dystonia after age 16 and was compound heterozygous for p.Arg148Cys and another missense variant. A sixth individual, who carried a missense variant in trans with the p.Arg148Cys variant, presented at age 13 with gradually worsening lower limb weakness and was diagnosed with mucopolysaccharidosis type IVB (Lei et al. 2012). Inheritance from an unaffected parent was demonstrated in multiple cases. Control data are unavailable for this variant, which is reported at a frequency of 0.000071 in the European (non-Finnish) population of the Genome Aggregation Database. COS-1 cells that transiently over-expressed the Arg148Cys GLB1 protein showed no residual β-galactosidase activity compared to cells that expressed the wildtype form (Caciotti et al. 2007), and cultured amniocytes, fibroblasts, and leukocytes from umbilical cord blood from a homozygous case showed decreased activity relative to the reference range (Kooper et al. 2006). Two other missense variants at same position have also been reported in association with GM1 gangliosidosis type 1. Based on the collective evidence, the p.Arg148Cys variant is classified as pathogenic for GLB1-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000818014 SCV000958605 pathogenic Mucopolysaccharidosis, MPS-IV-B; GM1 gangliosidosis 2020-08-30 criteria provided, single submitter clinical testing This sequence change replaces arginine with cysteine at codon 148 of the GLB1 protein (p.Arg148Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine. This variant is present in population databases (rs192732174, ExAC 0.003%). This variant has been observed in several individuals affected with GM1 gangliosidosis or mucopolysaccharidosis type IV (PMID: 15986423, 23151865, 17221873, 25936995). ClinVar contains an entry for this variant (Variation ID: 92907). Experimental studies have shown that this missense change abrogates GLB1 enzymatic activity (PMID: 17221873). The observation of one or more missense substitutions at this codon (p.Arg148Cys and p.Arg148Ser) in affected individuals suggests that this may be a clinically significant residue (PMID: 10839995, 15986423, 23151865, 17221873, 25936995). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV001331203 SCV001523191 pathogenic Infantile GM1 gangliosidosis 2020-07-09 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.